Self-Assembly Of Retinoid Nanoparticles For Melanoma Therapy

References

• Daenen S, Vellenga E, van Dobbenburgh OA, Halie MR. Retinoic acid as antileukemic therapy in a patient with acute promyelocytic leukemia and aspergillus pneumonia. Blood. 1986;67(2):559–561.3455829
   PubMed Web of Science ®Google Scholar
• Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988;72(2):567–572.3165295
   PubMed Web of Science ®Google Scholar
• Liang C, Yang L, Guo S. All-trans retinoic acid inhibits migration, invasion and proliferation, and promotes apoptosis in glioma cells in vitro. Oncol Lett. 2015;9(6):2833–2838. doi:10.3892/ol.2015.312026137156
   PubMedGoogle Scholar
• Teppola H, Sarkanen JR, Jalonen TO, Linne ML. Morphological differentiation towards neuronal phenotype of SH-SY5Y neuroblastoma cells by estradiol, retinoic acid and cholesterol. Neurochem Res. 2016;41(4):731–747. doi:10.1007/s11064-015-1743-626518675
   PubMedGoogle Scholar
• Freemantle SJ, Spinella MJ, Dmitrovsky E. Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene. 2003;22(47):7305–7315. doi:10.1038/sj.onc.120693614576840
   PubMed Web of Science ®Google Scholar
• Schenk T, Stengel S, Zelent A. Unlocking the potential of retinoic acid in anticancer therapy. Br J Cancer. 2014;111(11):2039–2045. doi:10.1038/bjc.2014.41225412233
   PubMed Web of Science ®Google Scholar
• Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today. 2006;11(17–18):812–818. doi:10.1016/j.drudis.2006.07.00516935749
   PubMed Web of Science ®Google Scholar
• Maeda H. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv Drug Deliv Rev. 2015;91:3–6. doi:10.1016/j.addr.2015.01.00225579058
   PubMed Web of Science ®Google Scholar
• Schultze E, Ourique A, Yurgel VC, et al. Encapsulation in lipid-core nanocapsules overcomes lung cancer cell resistance to tretinoin. Eur J Pharm Biopharm. 2014;87(1):55–63. doi:10.1016/j.ejpb.2014.02.00324525073
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang H, Lv X, et al. Enhancement of all-trans retinoic acid-induced differentiation by pH-sensitive nanoparticles for solid tumor cells. Macromol Biosci. 2014;14(3):369–379. doi:10.1002/mabi.20130029524115498
   PubMedGoogle Scholar
• Dummer R, Beyer M, Hymes K, et al. Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition. Leuk Lymphoma. 2012;53(8):1501–1508. doi:10.3109/10428194.2012.65662522239668
   PubMed Web of Science ®Google Scholar
• Fouladi M, Park JR, Stewart CF, et al. Pediatric phase I trial and pharmacokinetic study of vorinostat: a children’s oncology group phase I consortium report. J Clin Oncol. 2010;28(22):3623–3629. doi:10.1200/JCO.2009.25.911920606092
   PubMed Web of Science ®Google Scholar
• Huang P, Wang D, Su Y, et al. Combination of small molecule prodrug and nanodrug delivery: amphiphilic drug–drug conjugate for cancer therapy. J Am Chem Soc. 2014;136(33):11748–11756. doi:10.1021/ja505212y25078892
   PubMed Web of Science ®Google Scholar
• Al-Sheddi ES, Al-Oqail MM, Saquib Q, et al. Novel all trans-retinoic acid derivatives: cytotoxicity, inhibition of cell cycle progression and induction of apoptosis in human cancer cell lines. Molecules. 2015;20(5):8181–8197. doi:10.3390/molecules2005818125961160
   PubMedGoogle Scholar
• Li HX, Zhao W, Shi Y, et al. Retinoic acid amide inhibits JAK/STAT pathway in lung cancer which leads to apoptosis. Tumour Biol. 2015;36(11):8671–8678. doi:10.1007/s13277-015-3534-826044560
   PubMedGoogle Scholar
• Ech-Chahad A, Minassi A, Berton L, Appendino G. An expeditious hydroxyamidation of carboxylic acids. Tetrahedron Lett. 2005;46(31):5113–5115. doi:10.1016/j.tetlet.2005.05.131
   Web of Science ®Google Scholar
• Mai A, Rotili D, Tarantino D, et al. Small-molecule inhibitors of histone acetyltransferase activity: identification and biological properties. J Med Chem. 2006;49(23):6897–6907. doi:10.1021/jm060601m17154519
   PubMedGoogle Scholar
• van de Loosdrecht AA, Nennie E, Ossenkoppele GJ, Beelen RH, Langenhuijsen MM. Cell mediated cytotoxicity against U 937 cells by human monocytes and macrophages in a modified colorimetric MTT assay. A methodological study. J Immunol Methods. 1991;141(1):15–22. doi:10.1016/0022-1759(91)90205-t1865120
   PubMed Web of Science ®Google Scholar
• Borowicz S, Van Scoyk M, Avasarala S, et al. The soft agar colony formation assay. J Vis Exp. 2014;92:e51998.
   Google Scholar
• Wang H, Wu H, Shen H, et al. A bimodal MRI and NIR liposome nanoprobe for tumor targeted molecular imaging. J Mater Chem B. 2015;3(45):8832–8841. doi:10.1039/C5TB01160D
   PubMed Web of Science ®Google Scholar
• Zhang R, Xing R, Jiao T, et al. Carrier-free, chemophotodynamic dual nanodrugs via self-assembly for synergistic antitumor therapy. ACS Appl Mater Interfaces. 2016;8(21):13262–13269. doi:10.1021/acsami.6b0241627176934
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. doi:10.3322/caac.2138728055103
   PubMed Web of Science ®Google Scholar
• Cohen SM, Ellwein LB. Genetic errors, cell proliferation, and carcinogenesis. Cancer Res. 1991;51(24):6493–6505.1742722
   PubMed Web of Science ®Google Scholar
• Sebastian C. Tracking down the origin of cancer: metabolic reprogramming as a driver of stemness and tumorigenesis. Crit Rev Oncog. 2014;19(5):363–382.25404151
   PubMedGoogle Scholar
• Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev. 2001;53(2):283–318.11356986
   PubMed Web of Science ®Google Scholar
• Shabaruddin FH, Chen LC, Elliott RA, Payne K. A systematic review of utility values for chemotherapy-related adverse events. Pharmacoeconomics. 2013;31(4):277–288. doi:10.1007/s40273-013-0033-x23529208
   PubMedGoogle Scholar
• Grigorian A, O’Brien CB. Hepatotoxicity secondary to chemotherapy. J Clin Transl Hepatol. 2014;2(2):95–102. doi:10.14218/JCTH.2014.0001126357620
   PubMedGoogle Scholar
• Jones DP, Chesney RW. Renal toxicity of cancer chemotherapeutic agents in children: ifosfamide and cisplatin. Curr Opin Pediatr. 1995;7(2):208–213.7787938
   PubMedGoogle Scholar
• Szkandera J, Gerger A, Liegl-Atzwanger B, et al. Uric acid levels in blood are associated with clinical outcome in soft-tissue sarcoma patients. Clin Chem Lab Med. 2015;53(3):493–497. doi:10.1515/cclm-2014-048625324451
   PubMedGoogle Scholar
• Yamauchi T, Negoro E, Lee S, et al. A high serum uric acid level is associated with poor prognosis in patients with acute myeloid leukemia. Anticancer Res. 2013;33(9):3947–3951.24023333
   PubMed Web of Science ®Google Scholar
• Liu Z, Que S, Xu J, Peng T. Alanine aminotransferase-old biomarker and new concept: a review. Int J Med Sci. 2014;11(9):925–935. doi:10.7150/ijms.895125013373
   PubMed Web of Science ®Google Scholar
• Sporn MB, Dunlop NM, Newton DL, Henderson WR. Relationships between structure and activity of retinoids. Nature. 1976;263:110. doi:10.1038/263110a0987541
   PubMed Web of Science ®Google Scholar
• Kamimura T, Miyamoto T, Harada M, Akashi K. Advances in therapies for acute promyelocytic leukemia. Cancer Sci. 2011;102(11):1929–1937. doi:10.1111/j.1349-7006.2011.02045.x21790894
   PubMedGoogle Scholar
• Singh-Joy SD, McLain VC. Safety assessment of poloxamers 101, 105, 108, 122, 123, 124, 181, 182, 183, 184, 185, 188, 212, 215, 217, 231, 234, 235, 237, 238, 282, 284, 288, 331, 333, 334, 335, 338, 401, 402, 403, and 407, poloxamer 105 benzoate, and poloxamer 182 dibenzoate as used in cosmetics. Int J Toxicol. 2008;27(Suppl 2):93–128. doi:10.1080/1091581080224459518830866
   PubMedGoogle Scholar
• Zhang W, Liu J, Li S, Chen M, Liu H. Preparation and evaluation of stealth tashinone IIA-loaded solid lipid nanoparticles: influence of poloxamer 188 coating on phagocytic uptake. J Microencapsul. 2008;25(3):203–209. doi:10.1080/0265204070185218118382927
   PubMed Web of Science ®Google Scholar
• Dimberg A, Bahram F, Karlberg I, Larsson LG, Nilsson K, Oberg F. Retinoic acid-induced cell cycle arrest of human myeloid cell lines is associated with sequential down-regulation of c-Myc and cyclin E and posttranscriptional up-regulation of p27(Kip1). Blood. 2002;99(6):2199–2206. doi:10.1182/blood.v99.6.219911877298
   PubMedGoogle Scholar
• Su B, Chen X, Zhong C, Guo N, He J, Fan Y. All-trans retinoic acid inhibits mesangial cell proliferation by up-regulating p21Waf1/Cip1 and p27Kip1 and down-regulating Skp2. J Nephrol. 2012;25(6):1031–1040. doi:10.5301/jn.500009022344541
   PubMedGoogle Scholar
• Zhang H, Rosdahl I. Expression of p27 and MAPK proteins involved in all-trans retinoic acid-induced apoptosis and cell cycle arrest in matched primary and metastatic melanoma cells. Int J Oncol. 2004;25(5):1241–1248.15492811
   PubMed Web of Science ®Google Scholar